Researchers developed three new MDMA variants (ODMA, TDMA, and SeDMA) that retain the therapeutic benefits while reducing side effects. These compounds affect mood-regulating brain structures similarly to MDMA but have fewer toxic breakdown products and lower interaction with serotonin receptors. The study suggests these variants could make psychotherapeutic use of MDMA safer. Further research is needed to confirm their efficacy and safety.
